Serum medroxyprogesterone acetate levels in new and repeat users of depot medroxyprogesterone acetate at the end of the dosing interval

被引:24
作者
Smit, J
Botha, J
McFadyen, L
Beksinska, M
机构
[1] Univ Witwatersrand, Dept Obstet & Gynaecol, Reprod Hlth Res Unit, ZA-4001 Durban, South Africa
[2] Univ KwaZulu Natal, Nelson R Mandela Sch Med, Dept Pharmacol, Durban, South Africa
[3] Pfizer Global Res & Dev, Clin Pharmacol, Sandwich, Kent, England
基金
英国惠康基金;
关键词
depot medroxyprogesterone acetate; progestagen-only injectable contraception; medroxyprogesterone acetate serum concentrations; South Africa;
D O I
10.1016/j.contraception.2003.09.005
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
In the absence of published data on serum medroxyprogesterone acetate (MPA) levels in South African users, this study examines such levels in new and repeat users of depot medroxyprogesterone acetate at the end of the dosing interval. The study was undertaken at three family-planning clinics in Durban, South Africa. Serum MPA levels were measured in 94 Black African, Indian and White women returning between 11 and 14 weeks after their last injection. The median serum MPA level was 0.88 (range, <0.04-1.77) ng/mL and wide interindividual variability was observed. Levels in all but one woman were higher than 0.1 ng/mL, the level at which ovulation is reported to resume. MPA levels were not found to vary according to weight, body mass index or ethnicity. Although there was a slight tendency towards higher MPA levels with longer duration of use (r = 0.13), the wide interindividual variability precluded the possibility of determining whether this was a real trend. A prospective study, using standardized assay techniques and following individual women, is required to further clarify this issue. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:3 / 7
页数:5
相关论文
共 19 条
[1]  
[Anonymous], 1981, Medical Journal of Australia
[2]  
ASHAN R, 1998, WHO REAGENT PROGRAMM, P31
[3]  
BASSOL S, 1984, FERTIL STERIL, V42, P216
[4]   Temporary discontinuation: a compliance issue in injectable users [J].
Beksinska, ME ;
Rees, HV ;
Smit, J .
CONTRACEPTION, 2001, 64 (05) :309-313
[5]  
*DEP HLTH S AFR ME, 1999, S AFR DEM HLTH SURV
[6]   METABOLISM OF INJECTABLE FORMULATIONS OF CONTRACEPTIVE STEROIDS IN OBESE AND THIN WOMEN [J].
FOTHERBY, K ;
KOETSAWANG, S .
CONTRACEPTION, 1982, 26 (01) :51-58
[7]  
FOTHERBY K, 1980, FERTIL STERIL, V34, P131
[8]   PHARMACOKINETIC STUDY OF DIFFERENT DOSES OF DEPO-PROVERA [J].
FOTHERBY, K ;
KOETSAWANG, S ;
MATHRUBUTHAM, M .
CONTRACEPTION, 1980, 22 (05) :527-536
[9]  
GARZAFLORES J, 1994, REPROD BIOL, P69
[10]   ENDOMETRIAL HISTOLOGY AND CIRCULATING LEVELS OF MEDROXYPROGESTERONE ACETATE (MPA), ESTRADIOL, FSH AND LH IN WOMEN WITH MPA INDUCED AMENORRHEA COMPARED WITH WOMEN WITH SECONDARY AMENORRHEA [J].
JEPPSSON, S ;
JOHANSSON, EDB ;
LJUNGBERG, O ;
SJOBERG, NO .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1977, 56 (01) :43-48